ArticleWorld journal of clinical cases2022

Refractory lymphoma treated with chimeric antigen receptor T cells combined with programmed cell death-1 inhibitor: A case report.

Cang-Jian Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.